Painkiller sale plan to US gives France major headache

Painkiller sale plan to US gives France major headache

This photograph taken on March 23, 2023, shows doliprane boxes on a pharmacy shelf, in Colomiers, southwestern France.
This photograph taken on March 23, 2023, shows doliprane boxes on a pharmacy shelf, in Colomiers, southwestern France.. Photo: Valentine CHAPUIS / AFP
Source: AFP

The planned sale of France's best-selling medical drug to US investors has caused the government a splitting headache after an outcry against the project from politicians on all sides.

Even President Emmanuel Macron is involved in the debate centred on a perceived "loss of sovereignty" if popular painkiller Doliprane falls into American hands.

Doliprane is the brand under which healthcare giant Sanofi sells paracetamol, a non-opioid analgesic for the alleviation of mild to moderate pain, and of fever.

In French pharmacies, the brand's colourful boxes often line entire shelf walls, and Doliprane comes in many doses -- from 100 mg for newborn babies to 1,000 mg for adults -- and in tablet, capsule, suppository and liquid forms.

It is so ubiquitous that French people call any paracetamol product Doliprane, even when it is made by a different manufacturer.

Read also

'Unsustainable' housing crisis bedevils Spain's socialist govt

Sanofi, which is France's biggest healthcare company and among the world's top 12, has found out over the past few days just how attached the French are to the drug.

Political and trade union reactions came in hard and fast after the company announced last week that it was in talks with New York-based private equity firm Clayton, Dubilier & Rice (CD&R) to sell a 50-percent controlling stake in its subsidiary Opella, which makes Doliprane along with other consumer healthcare products.

The planned spinoff, it said, would be part of Sanofi's strategy to focus less on over-the-counter medication and more on innovative medicines and vaccines, including for polio, the flu and meningitis.

Macron said France has the means to prevent the sale
Macron said France has the means to prevent the sale. Photo: Ludovic MARIN / POOL/AFP
Source: AFP

"This is another symbol for the loss of our sovereignty," thundered Fabien Roussel, France's Communist party leader, calling the planned sale "shameful".

Read also

Starmer vows to cut red tape as he urges foreign investors to 'back' UK

At the other end of the political spectrum Jordan Bardella, president of the farright RN party, said that "the piecemeal sale of France carries on".

'Protect France'

Green party deputy Marine Tondelier said the government had "learned nothing" from the Covid pandemic when France suffered from medication bottlenecks blamed mostly on the outsourcing of production to foreign countries.

An adhoc group of centre-right lawmakers -- including from Macron's party -- meanwhile stated that the sale represented "a very worrying risk for our national security".

Boris Vallaud, parliamentary leader for the Socialists, reminded the government of 2022 when a sharp rise in demand for paracetamol caused some shortages in French pharmacies.

"Already some months ago, paracetamol was nowhere to be found," he said. "And now they want to give it up completely?"

Sanofi is France's top healthcare company
Sanofi is France's top healthcare company. Photo: Lou BENOIST / AFP
Source: AFP

In a message to Finance Minister Antoine Armand -- in the job only since last month -- the group of deputies said the planned sale went against "the re-establishment of France's sovereignty in the health sector".

Read also

Automaker Stellantis says CEO will retire in 2026

The government had the legal option, they said, of posing conditions or blocking the sale on the grounds that it concerns a "sensitive" industry.

Macron himself entered the fray Monday, saying that "the government has the instruments needed to protect France" from any unwanted "capital ownership".

The American investment fund is offering more than 15 billion euros ($16.4 billion) for Opella, according to Les Echos, a French business daily.

Faced with the protests, Armand on Friday told Sanofi and the potential buyer that Opella's "headquarters and decision-making centres" had to remain in France.

On Monday, Industry Minister Marc Ferracci said that current production also had to stay, "to safeguard employment and to secure supply for French people".

The same went for research and development facilities, he said.

Speaking to broadcaster France 3, Ferracci said the government would invoke a procedure for the control of foreign investment if the buyers failed to meet the demands.

Read also

Your 'local everything': what 7-Eleven buyout battle means for Japan

But he added: "I honestly believe that those commitments will be made."

PAY ATTENTION: Сheck out news that is picked exactly for YOU ➡️ find the “Recommended for you” block on the home page and enjoy!

Source: AFP

Authors:
AFP avatar

AFP AFP text, photo, graphic, audio or video material shall not be published, broadcast, rewritten for broadcast or publication or redistributed directly or indirectly in any medium. AFP news material may not be stored in whole or in part in a computer or otherwise except for personal and non-commercial use. AFP will not be held liable for any delays, inaccuracies, errors or omissions in any AFP news material or in transmission or delivery of all or any part thereof or for any damages whatsoever. As a newswire service, AFP does not obtain releases from subjects, individuals, groups or entities contained in its photographs, videos, graphics or quoted in its texts. Further, no clearance is obtained from the owners of any trademarks or copyrighted materials whose marks and materials are included in AFP material. Therefore you will be solely responsible for obtaining any and all necessary releases from whatever individuals and/or entities necessary for any uses of AFP material.